Veracyte, Inc. (VCYT)
Develops genetic tests that identify cancer types and risk in thyroid, prostate, breast, and lung tissue.
$55.86+0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+136.3%
The outlook
Veracyte trades at $55.86 with analyst consensus leaning Buy, though the average price target sits about 1% below current levels. The stock is positioned well above both its 50- and 200-day moving averages and sits near the upper end of its 52-week range. The valuation remains elevated at a trailing P/E of 51.7.
What’s behind the score
Analyst consensusBuy — 1.7 avg of 11 analysts
Price trendAbove its 50- & 200-day averages
52-week range87% of the way from its 52-week low to high
Price targetAvg target +1% vs current price
Analyst price target
~12-month · 11 analysts$56.55average target+1.2% vs now
Now $55.86
Low $45.00High $70.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$4.46B
52-wk high
$60.91
52-wk low
$22.92
50-day avg
$52.18
200-day avg
$41.50
Trailing P/E
51.7